🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522707-26-00
Authorised Phase I

A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer

2025-522707-26-00 · tracked via the Priya Life Science EU tracker
Sponsor
Novartis Pharma AG
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
15/09/2026
Enrollment target
5
Sites
Italy

Condition studied

Advanced HR+/HER- breast cancer

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522707-26-00 on CTIS ↗ ← All trials in the EU